Nick Teoh

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Serge Steinfeld, Laure Tant, Gerd R Burmester et al. · Arthritis Research & Therapy · 2006 · 257 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

Franck Morschhauser, John P. Leonard, Luis Fayad et al. · Journal of Clinical Oncology · 2009 · 165 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma

Sandra J. Strauss, F. Morschhauser, Jürgen Rech et al. · Journal of Clinical Oncology · 2006 · 149 citations · Full text

Medicine, Immunology, Oncology +16

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

Franck Morschhauser, Françoise Kraeber‐Bodéré, William A. Wegener et al. · Journal of Clinical Oncology · 2010 · 114 citations

Medicine, Hematology, Oncology +15

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

Seza A. Güleç, Steven J. Cohen, Kenneth Pennington et al. · Clinical Cancer Research · 2011 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17